Saphnelo is a medicine used as an add-on treatment in adults with systemic lupus erythematosus (SLE), a disease in which the immune system (the body’s natural defences) attacks normal cells and tissues, causing inflammation and organ damage. Saphnelo is given to patients who have antibodies against their own cells (autoantibodies) and whose disease is still moderate to severe despite standard treatment. Saphnelo contains the active substance anifrolumab.
Therapeutic Indication
### Therapeutic indication Saphnelo is indicated as an add-on therapy for the treatment of adult patients with moderate to severe, active autoantibody-positive systemic lupus erythematosus (SLE), despite standard therapy.
Therapeutic Area (MeSH)
ATC Code
L04AG11
ATC Item
anifrolumab
Pharmacotherapeutic Group
Monoclonal antibodies
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| anifrolumab | N/A | 阿尼芦单抗 |
EMA Name
Saphnelo
Medicine Name
Saphnelo
Aliases
N/ANo risk management plan link.
